News for Plus Therapeutics, Inc. (PSTV)

HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. ( PSTV) (the ”œCompany” or ”œPlus Therapeutics”), a clinical-stage pharmaceutical co

We recently published an article titled Micro-, Small-Cap Firms Dominate Market Rally. In this article, we are going to take a look at where Plus Therapeutics, Inc.

Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung cancer treatment.

Texas-based Intuitive Machines, Inc. (LUNR) is down over 35 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Rhenium (186Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium (186Re)

**media[560119]**

U.S. stock futures rose on Friday following Thursday's selloff that pushed the Nasdaq 100 index into the correction zone.

March 6, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biot...

Plus Therapeutics (PSTV) soars with FDA's Orphan Drug Designation for Rhenium Obisbemeda, targeting rare leptomeningeal metastases.

**media[558449]**

ReSPECT- LM Phase 1 single dose is now complete, and the recommended Phase 2 dose (RP2D) for single administration therapy has been determined AUSTIN, Texas,

**media[550860]**

Russell Bradley Named President & General Manager of CNSide Dr. Marc Hedrick, Rick Hawkins, and Russell Bradley Join CNSide Board of Directors Dr. Jonathan St

**media[548366]**

**media[545503]**

$3.7 Million Private Placement Financing from Existing Investors $2.0 Million Funding Advance from the Cancer Prevention and Research Institute of Texas (CPRIT

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA

META_DESC_INVESTMENT_IDEA